VBI Vaccines (VBIV) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
VBI Vaccines Inc. is presenting new Phase 2b interim data on their cancer vaccine, VBI-1901, targeting recurrent glioblastoma, at the 2024 ASCO Annual Meeting. The data includes promising results from initial patients and additional findings from newly added participants. The study, which aims to show significant improvements in overall survival, is a key factor for FDA approval of new oncology treatments.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.